380 related articles for article (PubMed ID: 32637413)
21. A Comprehensive Review of Immunoreceptor Regulation of Osteoclasts.
Humphrey MB; Nakamura MC
Clin Rev Allergy Immunol; 2016 Aug; 51(1):48-58. PubMed ID: 26573914
[TBL] [Abstract][Full Text] [Related]
22. Fibroblastic stromal cells express receptor activator of NF-kappa B ligand and support osteoclast differentiation.
Quinn JM; Horwood NJ; Elliott J; Gillespie MT; Martin TJ
J Bone Miner Res; 2000 Aug; 15(8):1459-66. PubMed ID: 10934644
[TBL] [Abstract][Full Text] [Related]
23. Leonurine hydrochloride inhibits osteoclastogenesis and prevents osteoporosis associated with estrogen deficiency by inhibiting the NF-κB and PI3K/Akt signaling pathways.
Yuan FL; Xu RS; Jiang DL; He XL; Su Q; Jin C; Li X
Bone; 2015 Jun; 75():128-37. PubMed ID: 25708053
[TBL] [Abstract][Full Text] [Related]
24. Aging increases stromal/osteoblastic cell-induced osteoclastogenesis and alters the osteoclast precursor pool in the mouse.
Cao JJ; Wronski TJ; Iwaniec U; Phleger L; Kurimoto P; Boudignon B; Halloran BP
J Bone Miner Res; 2005 Sep; 20(9):1659-68. PubMed ID: 16059637
[TBL] [Abstract][Full Text] [Related]
25. Osteoclast fusion and regulation by RANKL-dependent and independent factors.
Xing L; Xiu Y; Boyce BF
World J Orthop; 2012 Dec; 3(12):212-22. PubMed ID: 23362465
[TBL] [Abstract][Full Text] [Related]
26. NF-kappaB p50 and p52 expression is not required for RANK-expressing osteoclast progenitor formation but is essential for RANK- and cytokine-mediated osteoclastogenesis.
Xing L; Bushnell TP; Carlson L; Tai Z; Tondravi M; Siebenlist U; Young F; Boyce BF
J Bone Miner Res; 2002 Jul; 17(7):1200-10. PubMed ID: 12096833
[TBL] [Abstract][Full Text] [Related]
27. SC-19220, antagonist of prostaglandin E2 receptor EP1, inhibits osteoclastogenesis by RANKL.
Tsujisawa T; Inoue H; Nishihara T
J Bone Miner Res; 2005 Jan; 20(1):15-22. PubMed ID: 15619665
[TBL] [Abstract][Full Text] [Related]
28. Necrostatin-7 suppresses RANK-NFATc1 signaling and attenuates macrophage to osteoclast differentiation.
Fuji H; Ohmae S; Noma N; Takeiri M; Yasutomi H; Izumi K; Ito M; Toyomoto M; Iwaki S; Takemoto K; Seo S; Taura K; Hida S; Aoyama M; Ishihama Y; Hagiwara M; Takeda N; Hatano E; Iwaisako K; Uemoto S; Asagiri M
Biochem Biophys Res Commun; 2018 Sep; 503(2):544-549. PubMed ID: 29800570
[TBL] [Abstract][Full Text] [Related]
29. Regulation of ITAM adaptor molecules and their receptors by inhibition of calcineurin-NFAT signalling during late stage osteoclast differentiation.
Zawawi MS; Dharmapatni AA; Cantley MD; McHugh KP; Haynes DR; Crotti TN
Biochem Biophys Res Commun; 2012 Oct; 427(2):404-9. PubMed ID: 23000414
[TBL] [Abstract][Full Text] [Related]
30. Canonical and non-canonical pathways of osteoclast formation.
Knowles HJ; Athanasou NA
Histol Histopathol; 2009 Mar; 24(3):337-46. PubMed ID: 19130404
[TBL] [Abstract][Full Text] [Related]
31. Regulatory mechanisms operative in osteoclasts.
Reddy SV
Crit Rev Eukaryot Gene Expr; 2004; 14(4):255-70. PubMed ID: 15663356
[TBL] [Abstract][Full Text] [Related]
32. BSP and RANKL induce osteoclastogenesis and bone resorption synergistically.
Valverde P; Tu Q; Chen J
J Bone Miner Res; 2005 Sep; 20(9):1669-79. PubMed ID: 16059638
[TBL] [Abstract][Full Text] [Related]
33. Regulation of osteoclast differentiation by fibroblast growth factor 2: stimulation of receptor activator of nuclear factor kappaB ligand/osteoclast differentiation factor expression in osteoblasts and inhibition of macrophage colony-stimulating factor function in osteoclast precursors.
Chikazu D; Katagiri M; Ogasawara T; Ogata N; Shimoaka T; Takato T; Nakamura K; Kawaguchi H
J Bone Miner Res; 2001 Nov; 16(11):2074-81. PubMed ID: 11697804
[TBL] [Abstract][Full Text] [Related]
34. Methylsulfonylmethane Inhibits RANKL-Induced Osteoclastogenesis in BMMs by Suppressing NF-κB and STAT3 Activities.
Joung YH; Darvin P; Kang DY; Sp N; Byun HJ; Lee CH; Lee HK; Yang YM
PLoS One; 2016; 11(7):e0159891. PubMed ID: 27447722
[TBL] [Abstract][Full Text] [Related]
35. Cell-based assay strategy for identification of motif-specific RANK signaling pathway inhibitors.
Chen T; Feng X
Assay Drug Dev Technol; 2006 Aug; 4(4):473-82. PubMed ID: 16945019
[TBL] [Abstract][Full Text] [Related]
36. Saurolactam inhibits osteoclast differentiation and stimulates apoptosis of mature osteoclasts.
Kim MH; Ryu SY; Choi JS; Min YK; Kim SH
J Cell Physiol; 2009 Dec; 221(3):618-28. PubMed ID: 19653230
[TBL] [Abstract][Full Text] [Related]
37. Selective tyrosine kinase inhibition of insulin-like growth factor-1 receptor inhibits human and mouse breast cancer-induced bone cell activity, bone remodeling, and osteolysis.
Logan JG; Sophocleous A; Marino S; Muir M; Brunton VG; Idris AI
J Bone Miner Res; 2013 May; 28(5):1229-42. PubMed ID: 23239200
[TBL] [Abstract][Full Text] [Related]
38. Maslinic acid suppresses osteoclastogenesis and prevents ovariectomy-induced bone loss by regulating RANKL-mediated NF-κB and MAPK signaling pathways.
Li C; Yang Z; Li Z; Ma Y; Zhang L; Zheng C; Qiu W; Wu X; Wang X; Li H; Tang J; Qian M; Li D; Wang P; Luo J; Liu M
J Bone Miner Res; 2011 Mar; 26(3):644-56. PubMed ID: 20814972
[TBL] [Abstract][Full Text] [Related]
39. Docosahexaenoic acid signaling attenuates the proliferation and differentiation of bone marrow-derived osteoclast precursors and promotes apoptosis in mature osteoclasts.
Kim HJ; Ohk B; Yoon HJ; Kang WY; Seong SJ; Kim SY; Yoon YR
Cell Signal; 2017 Jan; 29():226-232. PubMed ID: 27836739
[TBL] [Abstract][Full Text] [Related]
40. Monocrotaline Suppresses RANKL-Induced Osteoclastogenesis In Vitro and Prevents LPS-Induced Bone Loss In Vivo.
Wei CM; Su YJ; Qin X; Ding JX; Liu Q; Song FM; Zong SH; Xu J; Zhou B; Zhao JM
Cell Physiol Biochem; 2018; 48(2):644-656. PubMed ID: 30025412
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]